Adjunctive Ziprasidone in the Treatment of Bipolar I Depression
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a treatment regimen of ziprasidone plus a mood
stabilizer is safe and effective in the short term treatment of Bipolar I Depression.
Ziprasidone will be added to lithium, valproate or lamotrigine after the patient has been on
a therapeutic dose of one of these mood stabilizers for at least 4 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.